Membranous Nephropathy: Antibody-based diagnosis, prognosis, and disease monitoring

Anti-PLA2R and anti-THSD7A are autoantibodies identified in primary membranous nephropathy (pMN) patients. The assessment of these antibodies can assist in the diagnosis, prognosis and follow up of patients. As the clinical disease correlates with immunological activity, antibody testing plays a central role in the laboratory work up in pMN. The webinar will be presented by Laurence H. Beck, Jr., MD, PhD. He is an Associate Professor for Medicine at the Boston University School of Medicine.

[@qizhang5777]

Deep appropriate for the great presentation!

[@Tingtong7130]

My son, 5, has MN. He was diagnosed at 3. He currently takes tacrolimous and prednisone. He has had rituximab but no remission yet.